LO-TROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LO-TROL (LO-TROL).

How it works

Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.

What the body does with it

Metabolism	Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Excretion	Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Half-life	The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Protein binding	Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Volume of Distribution	Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
Bioavailability	Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Onset of Action	After oral administration, clinical effect (e.g., reduction in blood pressure) is observed within 30–60 minutes. For intravenous administration, onset occurs within 2–5 minutes.
Duration of Action	Duration of action following a single oral dose is 8–12 hours based on blood pressure reduction. With intravenous administration, duration is 4–6 hours. Extended-release formulations provide coverage for 24 hours.

Classification & Brands

Dosing & administration

IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.

Dosage form	TABLET
Renal impairment	GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Pediatric use	0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Geriatric use	Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LO-TROL (LO-TROL).

Breastfeeding	LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Teratogenic Risk	LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to loteprednol etabonate or any component of the formulation","Active epithelial herpes simplex keratitis (dendritic keratitis)","Fungal diseases of ocular structures","Untreated eye infections (bacterial, viral, mycobacterial)"]

Clinical Precautions

Precautions

["Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation.","Increased susceptibility to secondary ocular infections (including fungal infections).","Masking of infection or worsening of existing infections.","Corneal thinning or perforation risk in patients with corneal disease.","Systemic absorption may occur with prolonged or high-dose use."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LO-TROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LO-TROL (LO-TROL).

How it works

Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.

What the body does with it

Metabolism	Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Excretion	Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Half-life	The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Protein binding	Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Volume of Distribution	Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
Bioavailability	Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Onset of Action	After oral administration, clinical effect (e.g., reduction in blood pressure) is observed within 30–60 minutes. For intravenous administration, onset occurs within 2–5 minutes.
Duration of Action	Duration of action following a single oral dose is 8–12 hours based on blood pressure reduction. With intravenous administration, duration is 4–6 hours. Extended-release formulations provide coverage for 24 hours.

Classification & Brands

Dosing & administration

IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.

Dosage form	TABLET
Renal impairment	GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Pediatric use	0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Geriatric use	Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LO-TROL (LO-TROL).

Breastfeeding	LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Teratogenic Risk	LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Clinical Precautions

Precautions

Clinical Tips & Counseling

Drug interactions

Loading safety data…